natgillin/translations-raw huggingface dataset:
A dosage form according to claim 7, characterized in that it is suitable for oral, intravenous, intraperitoneal, intradermal, intrathekal, intramuscular, intranasal, transmucosal, subcutaneous, or rectal administration. 
Oblik doziranja prema zahtjevu 7, naznačen fime da je pogodan za oralnu, intravenoznu, intraperitonealnu, intradermalnu, intratekalnu, intramuskularnu, intranazalnu, transmukoznu, potkožnu, ili rektalnu primjenu.
In another embodiment, the first and/or second polypeptide further comprises a variable heavy chain (VH) domain and a variable light chain (VL) domain. 
(a) prvi polipeptid obuhvaća domenu varijabilnog teškog lanca (VH) koja obuhvaća VH-HVR1, VH-HVR2 te VH-VHR3; (b) drugi polipeptid obuhvaća domenu varijabilnog lakog lanca (VL) koja se sastoji od VL-HVRI1, VL-HVR2 te VH-HVR3;
The method of claim 15, wherein at least about 99% of the protein present in the liquid mixture is recovered in the filtrate. 
Metoda prema patentnom zahtjevu 17, naznačena time da je najmanje 99% vWF prisutnog u tekućoj mješavini nađeno u filtratu.
Enantiomers may be separated through the formation of diastereomeric salts, e.g., by salt formation with an enantiomer-pure chiral acid, or by means of chromatography, e.g., by HPLC, using chromatographic substrates with chiral ligands. 
Enantiomeri se mogu rastaviti tvorbom diastereomernih soli, npr. tvorbom soli s enantiomerno čistom kiralnom kiselinom, ili kromatografijom, npr. pomoću HPLC, upotrebom kromatografskih podloga s kiralnim ligandima.
In some instances, the medium salt buffer further comprises between 1 and 100 mM phosphate. In some instances, the medium salt buffer elutes the rAAV particles without eluting rAAV particles with empty capsids, partially denatured capsids, less infectious capsids, and/or partially full capsids. 
Postupak prema bilo kojem od zahtjeva 1 do 8, naznačen time što je populacija čestica rAAV s praznim kapsidima, djelomično denaturiranim kapsidima, manje zaraznim kapsidnim materijalom, i/ili djelomično punim kapsidima vezana na HIC medij nakon eluiranja s puferom srednje koncentracije soli.
adding sulphide to said first leach solution, causing precipitation of sulphides of heavy metals; and 
dodavanje (212, 232) sulfida u spomenutu prvu otopinu za ispiranje, čime se izaziva taloženje sulfida teških metala; i
The object according to claim 9, further characterized in that said object is in the form of a sheet. 
Predmet prema zahtjevu 6, naznačen time što je navedeni objekt u obliku lista.
The process of claim 1 in which the step of melting the solid raw material mix in the submerged combustion melter comprises generating a substantially toroidal melt flow pattern in the melt, having a substantially vertical central axis of revolution, comprising major centrally inwardly convergent flows at the melt surface. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time što se korak taljenja mješavine čvrstih sirovina u talioniku s uronjenim izgaranjem sastoji u postizanju uglavnom toroidnog uzorka toka taline u talini, koji ima uglavnom okomitu središnju os kruženja, koji se sastoji od glavnih tokova koji konvergiraju prema središtu na površini taline.
U2N, and if, at the same time, status signal (D1) is present and the status signal (D2) is absent. 
U2N, i ako je, u isto vrijeme, napon u SN napajanju (2.11) kapacitivnog djelitelja napona (2.5) SN razvodnog uređaja (2) prisutan i prekidač odvajanja (2.1) je isključen.
H-indazole-3-carboxamide for the use according to claim 12, wherein said mood disorders are selected from the group consisting of bipolar disorders and depressive disorders. 
H-inđazol-3-karboksamid za uporabu prema zahtjevu 12, naznačen time, da su navedeni poremećaji raspoloženja, odabrani iz skupine koju čine bipolarni poremećaji i depresivni poremećaji.
Accordingly, the invention is not limited except as by the appended claims. An orally disintegrating solid pharmaceutical composition comprising less than or equal to about 20 mg of a topically administrable corticosteroid and at least one disintegrant, wherein the solid pharmaceutical composition has no significant systemic glucocorticoid or mineralocorticoid activity after oral administration, 
PATENTNI ZAHTJEVI Tableta za oralno disperziranje koja sadrži manje ili jednako 20 mg budezonida ili njegovog solvata ili estera i najmanje jedan farmaceutski prihvatljiv sastojak koji omogućuje razgradnju tablete u usnoj šupljini, naznačeno time da je tableta pogodna za topikalnu primjenu budezonida u gornjem gastrointestinatnom traktu.
The process according to claim 11 wherein said aprotic solvent is dimethyl acetamide. 
Postupak prema patentnom zahtjevu 11 gdje navedeno aprotonsko otapalo jest dimetil acetamid.
Q' is MeLeu, Y-hydroxy-MeLeu or MeAla. or a pharmaceutically acceptable salt thereof. 
Q' je MeLeu, y-hidroksi-MeLeu ili MeAla, ili njegova farmaceutski prihvatljiva sol.
said DNA probe comprises SEQ ID NO:1 or SEQ ID NO:2 or complement thereof; and/or 
se spomenuta DNA proba sastoji od SEQ ID NO: 1 ili SEQ ID NO: 2 ili njihovih komplementarnih sekvenci; i / ili
Use according to claims 1 to 4 wherein the composition is at least 50% protective, in a population of vaccinated individuals, against diarrhea and/or gastroenteritis and/or severe gastroenteritis caused by infection of a rotavirus of at least two non-G1 serotypes. 
Upotreba u skladu s patentnim zahtjevima 1 do 5, naznačena time što pripravak štiti najmanje 50% u populaciji osoba cijepljenih protiv proljeva i/ili gastroenteritisa i/ili teškog gastroenteritisa uzrokovanih infekcijom rotavirusom iz najmanje dva ne-G1 serotipa.
EP 0 797 991 and EP 1 028 718 describe coated spheroids of venlafaxine hydrochloride, wherein a spheroid core, prepared by extruding and spheronizing a mixture of the drug with microcrystalline cellulose and hydroxypropylmethyl cellulose (HPMC), is coated with a mixture of ethyl cellulose and hydroxypropylmethyl cellulose. 
Dokumenti EP 0 797 991 i EP 1 028 718 opisuju obložene sferoide venlafaksin-hidroklorida, gdje je sferoidna jezgra, dobivena ekstruzijom i sferonizacijom smjese lijeka s mikrokristalnom celulozom i hidroksipropilmetilcelulozom (HPMC), obložena smjesom etilceluloze i hidroksipropilmetilceluloze.
In one embodiment the first proximal end is within a short repeat. 
Polipeptid u skladu s patentnim zahtjevom 6, naznačen time što je prvi proksimalni kraj unutar ponavljanog dijela VII toksina A.
A fighting module of claim 1, wherein said microchip is configured to operate the switching device such that 330 mA to 370 mA is delivered to the light emitting diode when said thermistor senses between 90°C to 100°C. 
Rasvjetni modul iz patentnog zahtjeva 1, naznačen time, da je navedeni mikročip konfiguriran da upravlja preklopnim sklopom tako da se LED diodi isporučuje 330 mA do 370 mA kada navedeni termistor odčita temperaturu u rasponu 90°C -100°C.
A compound according to claim 1 that is (4-cyclopropyl-piperazin-1-yl)-(4-morpholin-4-ylmethyl-phenyl)-methanone, or an enantiomer, hydrate, solvate, or pharmaceutically acceptable salt thereof. 
Spoj u skladu sa zahtjevom 1, naznačen time, da je (4-ciklopropil-piperazin-1-il)-[4-(4-fluoro-piperidin-1-ilmetil)-fenil]-metanon ili njegov enantiomer, hidrat, solvat ili farmaceutski prihvatljiva sol.
The isolated DNA of claim 21, wherein the recombinant adenosine deaminase has an amino acid substitution selected from the group consisting of Gln in place of Lys198; Ala in place of Thr245; Arg in place of Gly351, and combinations thereof. 
Izolirana DNA u skladu s patentnim zahtjevom 21, naznačena time, da rekombinantna adenozin deaminaza ima aminokiselinsku supstituciju izabranu iz skupine koju čine Gln umjesto Lys198; Ala umjesto Thr245; Arg umjesto Gly351, i njihove kombinacije.
In analogy to example 1, 1.5 kg of diphenylsilandiol were used instead of hexamethyldisilazane. It was added in finely powdered form by means of a feeding screw. 
Analogno Primjeru 1 umjesto heksametildisilazana koristi se 1.5 kg difenilsilandiola, koji se u obliku sitnog praha dodaje pomoću dovodnog vijka.
US 2,574,737 discloses an elastic stocking whose main or body portion is knitted of plain stitches and the yarn employed comprises a central core of rubber around which one or more strands of fibrous material is wound in a helical form. 
US 2,574,737 opisuje elastičnu visoku čarapu, čiji je glavni ili tjelesni dio ispleten od ravnih očica, a upotrijebljeni konac ima središnju jezgru od gume oko koje je u obliku spirale omotana jedna ili je omotano više traka vlaknastog materijala.
sealing said second substrate on top of said patterned first substrate, so that said second substrate acts as a cover lid. 
- hermetičkog prekrivanja navedenog strukturiranog prvog supstrata navedenim drugim supstratom, tako da navedeni drugi supstrat djeluje kao poklopac.
In such methods, the cell can also be a mammalian cell, human cell, a non-human mammalian cell, a non-human cell, a cell from a rodent, a rat, a mouse, a hamster, a fibroblast cell or any other host cell. 
Postupak sukladno patentnom zahtjevu 1 ili 2, naznačen time, da je ta stanica stanica sisavca, po izboru gdje stanica sisavca je iz glodavca, i izborno gdje taj glodavac štakor ili miš.
The pharmaceutical composition of claim 5 or claim 6, wherein the amount of the corresponding sulfoxide does not increase by more than 0.5% by weight, preferably more than 0.3% by weight, preferably more than 0.1% by weight of the initial amount of montelukast after storage at about 40°C and about 75% relative humidity for 3 months. 
Farmaceutska kompozicija prema patentnom zahtjevu 5, naznačena time što se količina odgovarajućeg sulfoksida ne povećava za više od 0.1 težinskih % od početne količine montelukasta poslije čuvanja na oko i oko 75% relativne vlažnosti u trajanju od 3 mjeseca.
In some embodiments the composition comprising nanoparticles comprising a taxane and albumin is administered parenterally. In some embodiments, the composition comprising nanoparticles comprising a taxane and albumin is administered intravenously, intraarterially, intrahepatically, or intraportally. 
Pripravak ili kombinacija za uporabu prema bilo kojem od zahtjeva 1-9, gdje se pripravak koji sadrži nanočestice s taksanom i albuminom primjenjuje parenteralno, poželjno intravenski, intraarterijski, intrahepatalno ili intraportalno.
The polymeric device material of claim 16 comprising 0.1-5% (w/w) of a polymerizable UV absorber and 0.01-0.5% (w/w) of a polymerizable colorant. 
Polimerni materijal za navedeni uređaj u skladu s patentnim zahtjevom 17, naznačen time što sadrži 0,1-5 % (težinski) polimerizabilnog UV apsorbera i 0,01-0,5 % (težinski) polimerizabilne boje.
The polypeptide of item 9, wherein the polypeptide exhibits a fibrinolytic activity that is inhibited by a2-antiplasmin at a rate of inhibition that is at least about 5-fold faster than the rate of inhibition of the fibrinolytic activity of mini-plasmin by a2-antiplasmin. 
Polipeptid prema zahtjevu 8, naznačen time da polipeptid pokazuje fibrinolitičku aktivnost koja je inhibirana s a2- antiplazminom pri stupnju inhibicije koji je najmanje oko 5 puta brži nego što je stupanj inhibicije fibrinolitičke aktivnosti mini-plazmina sa 62-antiplazminom.
The expression of the 7-dehydrocholesterol reductase and 3B-hydroxysterol A24-reductase enzymes and the inactivation of the C-22 sterol desaturase and sterol 24-C-methyltransferase enzymes are carried out as described above. 
Soj kvasca koji proizvodi desmosterol, naznačen time da nema funkcionalnu kopiju gena koji kodira enzim 24-C- metiltransferazu (erg6) i time da eksprimira heterologni enzim 7-dehidrokolesterol reduktazu.
Yield: 29%; brown solid. 
Prinos: 29%; smeđe čvrsta supstanca.
Compound according to anyone of the preceding claims wherein represents a -Cycloalkyl< group wherein (CO2R") and (COR"') are attached to the same atom of the Z ring. 
A predstavlja -Cikloalkil< skupinu, gdje (CO2R") 1(COR'"') su vezani na isti atom u Z prstenu.
A method of treating a subject with an infectious disease, or at risk of becoming infected with an infectious disease, or with cancer, or at risk of developing cancer, comprising selecting a subject in need of treatment and administering to the subject the recombinant RhCMV or HCMV vector of any one of paragraphs 1-20, or the composition of paragraph 21. 
Rekombinantni vektor RRCMYV ili HCMV u skladu s bilo kojim od patentnih zahtjeva 1-11, ili pripravak u skladu s patentnim zahtjevom 12, naznačen time što je namijenjen upotrebi u postupku liječenja subjekta sa zaraznom bolešću, ili je u opasnosti od zaražavanja zaraznom bolešću, ili s rakom, ili je u opasnosti od razvoja raka.
The additional air stream is necessary in order to take in the aerosol 24 by inhalation. 
U aerosolu 24 je potrebna dodatna struja zraka za njegovo uzimanje inhalacijom.
In some embodiments, the other agent inhibits a molecule that promotes microtubule disassembly directly or indirectly. 
Pripravak ili kombinacija za uporabu prema zahtjevima 1 do 3, gdje drugo sredstvo inhibira molekulu koja potiče rastavljanje mikrotubula izravno ili posredno.
Normally such a vial has a mouth opening bounded by a flange-shaped rim, and the closure part is held in a closing relationship with the mouth opening by a flexible metal clamp part which surrounds the perimeter of the closure part and holds it tightly against the rim. 
Normalno ima takva bočica ulazni otvor koji je omeđen rubom koji ima oblik prirubnice, a element za zatvaranje se drži u zatvorenom položaju u odnosu na ulazni otvor pomoću fleksibilnog metalnog steznog elementa koji obuhvaća opseg elementa za zatvaranje i drži ga čvrsto uz rub bočice.
Use according to claim 11, wherein the oncological disease is selected from the group consisting of solid tumours. 
Uporaba u skladu sa zahtjevom 11, naznačena time, da onkološko oboljenje je izabrano iz skupine koju čine čvrsti tumori.
subsequently concentrating the aqueous reaction mixture such that precipitates of pyrophosphate do not form; 
(iii) naknadno koncentriranje vodene reakcijske smjese tako da se ne odvija taloženje pirofosfata;
A combination for use according to claim 5 wherein the B2 agonist is salmeterol xinafoate. 
Kombinacija sukladno patentnom zahtjevu 4, naznačena time, da je kortikosteroid mometazon furoat.
Cosmetic composition according to one of claims 1 to 4, characterized in that the compound of general formula (I) is chosen from the group constituted of: 
Spoj prema jednom od zahtjeva 1 do 4, naznačen time da je odabran iz skupine koja sadrži:
A compound of formula (IB), or a tautomer, mesomer, raceme, enantiomer, diastereomer, and mixture thereof: wherein: L is a bond or alkyl; 
Postupak pripreme spoja formule (I), ili njegov tautomer, mezomer, racemat, enantiomer, dijastereomer i smjese, i njegove farmaceutski prihvatljive soli, koji sadrži korake:
wherein X1, X2, R1, R3, A3, L1 and n are as defined above and when L1 is nitro, said nitro group is reduced to an amino group and the amino derivative obtained is then reacted with a compound of formula III G-A4 b -L0 (III), 
(XXXVII). gdje su X1, X2, R1, R3, A3, L1 in definirani kao gore; i kada je LI nitro, navedenu nitro skupinu se reducira u amino skupinu, a dobiveni amino derivat zatim reagira sa spojem formule III G-A4b-L0 (III), gdje
The method or the mixture according to claim 4, wherein the antibodies are derived from mammals, such as human, mice or rats. 
Postupak prema zahtjevu 1, naznačen time što je antitijelo dobiveno od sisavaca, poželjno čovjeka, miševa ili štakora.
Use of aminopyridine in the manufacture of a sustained release composition for increasing the walking speed of a patient with multiple sclerosis, said composition to be administered as a stable dose treatment twice daily in a therapeutic dose of 15 milligrams or less of aminopyridine. 
. Upotreba aminopridina u proizvodnji sastava s odgođenim oslobađanjem za tretiranje multiple skleroze, naznačena time da je sastav primijenjen dvaput dnevno u dozi od 10 miligrama ili manjoj, aminopiridina.
Improvement of the flow properties; 
- < poboljšanje svojstava strujanja tekućih proizvoda;
“Substituted heteroaralkyl” means heteroaralkyl substituted in the manner described above for substituted alkyl. 
Â« Supstituirani heteroaralkil Â« znači heteroaralkil supstituiran na način opisan iznad za supstituirani alkil.
During or after the application of the liquid polyurethane layer against the molding wall 1, at those points where such is deemed necessary, channel parts 7 are provided, which are manufactured from sufficiently flexible material and glued onto the preformed air-tight covering 3. 
Tijekom ili nakon nanošenja tekućeg poliuretanskog sloja na stijenku kalupa 1, na onim mjestima gdje se smatra da su oni potrebni, predviđeni su dijelovi kanala 7, koji su izrađeni od dovoljno savitljivog materijala i zaljepljeni na prethodno oblikovan neprodušan pokrov 3.
SEQ ID NO: 8 or a variant thereof, wherein said variant comprises one, two or three conservatively modified amino acid substitutions; 
sekv. id. br.: 8 ili njena varijanta, pri čemu navedena varijanta sadrži jednu, dvije ili tri konzervativno modificirane aminokiselinske supstitucije;
The carbamate analog of 42-O-(D-Fructosylcarbonyl)rapamycin is formed from an amino sugar wherein the carbohydrate moiety is attached to the carbonyl linker through the amino nitrogen atom of the amino sugar, thereby forming a carbamate linkage. 
Karbamatni analog 42-O0-(D-fruktozilkarbonil)rapamicin dobiven je iz amino-šećera gdje je ugljikohidratna jedinica pričvršćena na karbonilni veznik kroz amino-dušikov atom amino-šećera, čime nastaje karbamatna veza.
separating insoluble residues from said dissolving step, thereby forming a first leach solution; 
razdvajanje (210) netopivih ostataka iz spomenutog koraka otapanja, čime se dobiva prva otopina za ispiranje;
The residue was purified by ion exchange chromatography (Bio-Rad AG 50W-X8, [Trade Mark], 200-400 mesh, cation form, 40 g) eluting with dioxane initially followed by 2% pyridine in water. 
Ostatak se pročisti jonoizmjenjivačkom kromatografijom (Bio-Rad AG 50W-X8 /Irgovačko ime/, 200-400 meša, kationski oblik, 40 g) eluiranjem s dioksanom na početku i onda s 2% piridinom u vodi.
The microcapsule suspension formulation according to claim 1, wherein the ratio of the suspended phase a) to the aqueous phase b) is from about 1:1 to about 1:7, preferably from about 1:1 to about 1:4. 
Suspenzijska formulacija mikrokapsula u skladu s patentnim zahtjevom 1, naznačena time što se omjer između suspendirane faze a) i vodene faze b) kreće od otprilike 1:1 do otprilike 1:7, po mogućnosti od otprilike 1:1 do otprilike 1:4.
The substance which irritates the nasal passages and/or pharynx of component (a) is preferably based on one or more constituents or one or more plant parts of at least one hot substance drug. 
Tvar komponente (a) koja nadražuje nosnu šupljinu ili šupljinu ždrijela zasniva se prvenstveno na jednom ili više sastojaka ili na jednom ili više biljnih dijelova barem jedne nadražujuće droge.
Adjuster nut 26 is threadedly received on threaded portion 53 . 
Navrtka 26 za podešavanje je navojem pričvršćena za navojni dio 53.
The packaging and the device for manual rolling of cigarettes as claimed in claim 1, further comprising variously shaped clamps may be arranged instead of the lugs (1 f) and openings (1 a ′). 
Pakiranje 1 uređaj za ručno motanje cigareta, prema zahtjevu 1 i 2, naznačen/o time, da umjesto uha (1f) i otvora (1a), mogu se rasporediti spone različitih oblika.
The inventive compounds also may be used to treat allergies and respiratory conditions, including asthma, acute respiratory distress syndrome, hayfever, allergic rhinitis, and any chronic pulmonary inflammatory disease such as chronic obstructive pulmonary disease. 
Uporaba spoja prema zahtjevu 10, naznačena time što se radi o upalnom poremećaju iz skupine koja obuhvaća astmu, sindrom respiratornog distresa kod odraslih, kroničnu opstruktivneu plućnu bolest, kroničnu plućnu inflamatornu bolest, dijabetes, upalnu bolest crijeva, osteoporozu, psorijazu, odbacivanja transplantanta, 15
PPARa is activated by a number of medium and long-chain fatty acids, and it is involved in stimulating B-oxidation of fatty acids. 
Niz masnih kiselina srednje dugog i dugog lanca aktivira PPARa, a sudjeluje u stimulaciji Boksidacije masnih kiselina.
The mixture was stirred at room temperature for 16 hours and evaporated. 
Smjesa se miješa na sobnoj temperaturi u tijeku 16 sati i uparava.
a stoma seal (22) is located at the first aperture (16) and coupled to the second wall (14); 
(c) stoma brtva (22) se nalazi na prvom otvoru (16) i spojena je s drugim zidom (14);
The compound of formula I, or a shalt thereof, for use according to claim 4, wherein the autoimmune disease or condition is multiple sclerosis. 
Spoj formule I, ili njegova sol, namijenjen upotrebi u skladu s patentnim zahtjevom 4, naznačen time što autoimuna bolest ili stanje je multipla skleroza.
reacting a compound of formula (IV) wherein X' is selected from chlorine, bromine, iodine and a triflate group (CF3SO3) with 1,2-dibromoethane to form a compound of formula (V) 
(IV) u kojoj je X* odabran od sljedećih: klor, brom, jod 1 triflatna skupina (CF3SO:) s 1,2-dibrometanom, pri čemu nastaje spoj formule (V),
Particular fungi that may be treated with a combination of the invention include Aspergillus fumigatus, Candida albicans, Cryptococcus neoformans, Histoplasma capsulatum and Pneumocystis jiroveci. 
Kombinacija za uporabu prema zahtjevu 5 naznačena time što je infekcija uzrokovana sa Aspergillus fumigatus, Candida albicans, Cryptococcus neoformans, Histoplasma capsulatum ili Pneumocystis jiroveci.
A beta2-adrenoceptor agonist as therapeutically active ingredient for use as a dermatological medicament in the topical administration to the skin of an individual in the local treatment of the skin of cutaneous forms of lupus erythematosus selected from the group consisting of Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus, Discoid Lupus Erythematosus, Lupus Panniculitis, and Lupus Erythematosus Profundus, in an individual, wherein the beta2-adrenoceptor agonist is defined by structural formula I, including a stereoisomer thereof and a pharmaceutically acceptable salt thereof, 
L Agonist beta2-adrenoceptora kao terapeutski aktivni sastojak za uporabu kao dermatološki lijek za topičku primjenu na kožu pojedinca za lokalno liječenje kože kutanih oblika eritemskog lupusa iz skupine koja se sastoji od subakutnog kutanog subakutnog kutanog eritemskog lupusa, kroničnog kutanog eritemskog lupusa, diskoidnog eritemskog lupusa, lupusa panikulitisa i eritemskog lupusa profundusa, kod pojedinca naznačen time da je agonist beta2-adrenoceptora određen sa strukturnom formulom I, uključujući njegove stereoizomere i njegovu farmaceutski prihvatljivu sol,
A process according to claim 21, wherein pressure is applied to the peripheral flange at a pressure of from 30 psi to 180 psi for a period of time of from 0.5 seconds to 5 seconds, preferably 110 psi for 1 second. 
Postupak prema patentnom zahtjevu 21, pri čemu se pritisak primjenjuje na obod pod tlakom od 206,84 KPa do 1241,06 KPa (30 psi do 180 psi) u periodu od 0,5 sekundi do 5 sekundi, poželjno 758,42 KPa (110 psi) u trajanju 1 sekunda.
The solid dispersion of one of clauses 11-24, wherein the N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide is present in an amount of from about 10% by weight to about 80% by weight. 
Kruta disperzija prema bilo kojem od zahtjeva 1 do 7, naznačena time da je N-[2,4-bis(1,1-dimetiletil)-5hidroksfenil|-1,4-dihidro-4-oksokinolin-3-karboksamid prisutan u količini od 10% masenih do 80% masenih.
2 b is a section through the individual arrangement 1 in its assembled or finished state. 
Slika 2b prikazuje presjek kroz pojedinačnu naprava 1 u njezinom složenom ili završenom stanju.
In still yet another embodiment, the sodium level is controllable less 300 ppm and the sulfate level is less than 0.6%. 
Prekursor materijal prema zahtjevu 10, u kome je razina natrija unutar prekursor materijala manja od 300 ppm.